2026– date –
-
Tenaya Therapeutics Presents Preclinical Data at ASGCT 2026 Showing PBGENE-DMD Gene Therapy Achieves Superior Efficacy in Early-Juvenile Duchenne Muscular Dystrophy Mice
Simply Wall St USA Overview Tenaya Therapeutics unveiled new preclinical data for its Duchenne muscular dystrophy (DMD) gene therapy candidate, PBGENE-DMD, at the 2026 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting. T... -
Apify Launches EU CTIS Scraper API: Revolutionizing Pharma Intelligence and Regulatory Oversight
Apify Czech Republic Overview Apify has introduced a new API designed to programmatically scrape vital clinical trial data from the EU Clinical Trials Information System (CTIS/EudraCT). This innovative tool significantly streamlines phar... -
BitLyft Outlines Future Trends in AI and Machine Learning for Cybersecurity: From Predictive Analytics to Automated Threat Hunting
BitLyft Unknown Overview BitLyft's article details the evolving role of AI and machine learning (ML) in cybersecurity, focusing on advanced threat detection, real-time response, and predictive capabilities. Key trends include AI-powered ... -
U.S. Department of Energy Clarifies Machine Learning Fundamentals: Pattern Detection in Massive Datasets for Predictions, a Specialized Form of AI
U.S. Department of Energy USA Overview The U.S. Department of Energy (DOE) has issued an explanation defining machine learning (ML) as a computational process for detecting patterns in vast datasets and making predictions. It clarifies M... -
ASCO 2026 Features AI-Augmented ctDNA Analysis for Prognostic Risk Stratification in Metastatic Clear Cell RCC, Pioneering GU Oncology Advancements
UroToday USA Overview UroToday's coverage of ASCO 2026 highlights several presentations in genitourinary oncology, prominently featuring an 'AI-Augmented Analysis of Quantitative ctDNA Burden and Longitudinal Kinetics to Identify Prognos... -
Expert Calls for AI/ML Intervention as Delayed Clinical Trial Reporting in China Sparks International Criticism
Facebook (STAT News) USA Overview Renewed criticism has emerged regarding lax clinical trial reporting practices in China, following a second delayed report of a child's death, highlighting severe regulatory compliance issues. The discus... -
TFSF Ventures Unveils AI Agent Solution for Enhanced Pharma Pipeline Competitive Intelligence
TFSF Ventures Unknown Overview TFSF Ventures highlights the application of AI agents for competitive intelligence in the pharmaceutical sector, specifically for pipeline tracking. These AI agents integrate data from critical sources such... -
Unlocking Drug Development Insights: AI-Powered CTO Benchmark Integrates LLMs and Multi-Source Data for Dynamic Clinical Trial Outcomes
Chufan Gao Unknown Overview Chufan Gao and colleagues have released the Clinical Trial Outcome (CTO) benchmark, a vast repository of 125,000 drug and biologic trials. This innovative platform integrates LLM interpretations, real-time tri... -
ASCO 2026 Reveals LITESPARK-022 Trial’s Significant DFS Improvement with Adjuvant Pembrolizumab Plus Belzutifan in Renal Cell Carcinoma
Oncodaily USA Overview New insights into adjuvant therapy for renal cell carcinoma (RCC) were presented at the 2026 ASCO Annual Meeting. The LITESPARK-022 trial demonstrated that adjuvant pembrolizumab combined with belzutifan significan... -
HER2-Targeted Regimen Achieves 60.2% Pathologic Complete Response Rate in Locally Advanced HER2-Positive Breast Cancer in China’s Phase II neoPICD Trial, Presented at ASCO Breakthrough 2026
The ASCO Post USA Overview A HER2-targeted regimen demonstrated a high pathologic complete response (pCR) rate of 60.2% in patients with locally advanced HER2-positive breast cancer in the phase II neoPICD trial conducted in China. Prese...
